Next Generation Sequencing has provided insights into the genetic diversity of Mycobacterium Tuberculosis, which are crucial for understanding the evolution and transmission of the disease, including the identification of drug-resistant strains, enabling rapid and accurate tailoring of treatment.

MGI has developed an ATOPlex Mycobacterium Tuberculosis targeted sequencing sample to report workflow, providing full and complete MTB identification and drug resistance analysis. Based on MGI’s ATOPlex multiplex PCR library preparation platform, 2-step amplification in one tube is needed to achieve target area amplification and library construction, supporting direct detection of nucleic acid extracted from sputum and lavage fluid samples.

Combined with MGI’s MTB-Explorer Software, provides identification of 174 types of mycobacteria, MTBC identification, spoligotyping, and evolutionary traceability analysis. Specifically for drug resistance, the software covers a total of 7000+ mutations, including all of the 1200+ first-and second-group drug resistance associated mutations associated with the “Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance" released by WHO for annotation.